Carbapenemases producer Gram negative bacilli infections : surveillance results 2014–2015
From April 1, 2014, to March 31, 2015, 67 healthcare facilities (participation rate: 75.2%) took part in the surveillance of carbapenemase-producing Gram negative bacilli (CPGNB) infections, for a total of 3,225,934 patient-days (Table 1).
In total, 9 CPGNB infections were reported among patients who acquired their strain during a current or previous hospital stay in the reporting facility (categories 1a + 1b). The incidence rate of healthcare-associated CPGNB infection (cat. 1a + 1b) was 0.028 / 10,000 patient days. The acquisition rate of healthcare-associated CPGNB colonization (cat. 1a + 1b) was 0.16 / 10,000 patient days. Data was extracted on May 20th, 2015 and updated on June 1, 2015 for complications.
Updated : March 24, 2016
Table 1 – Participation of Healthcare Facilities in the Surveillance of CPGNB Infections, Québec, 2014-2015
2014-2015 | |
---|---|
Participating facilities (N) | 67 |
Admissions (N) | 432,363 |
Inpatient-days (N) | 3,225,934 |
Cases of healthcare-associated CPGNB infection (cat. 1a + 1b) (N) | 9 |
Cases of healthcare-associated CPGNB colonization (cat. 1a + 1b) (N) | 52 |
Infected patients (N) | 8 |
Incidence rate
In 2014–2015, the incidence rate of healthcare-associated CPGNB infection (cat. 1a + 1b) was 0.028/10,000 patient-days (table 2).
Teaching healthcare facilities have a higher incidence rate of healthcare-associated CPGNB infection than non teaching facilities (table 2).
Table 2 – Incidence Rate and Percentile Distribution of Healthcare-Associated CPGNB Infection (Cat. 1a + 1b) by Type of Healthcare Facility, Québec, 2014–2015 (Incidence Rate per 10,000 Patient-Days [95% CI])
Type of Facility | Min. | 25 % | 50 % | 75 % | 90 % | Max. | Incidence Rate |
---|---|---|---|---|---|---|---|
Non-teaching (N = 45) | 0.057 | 0.057 | 0.057 | 0.057 | 0.057 | 0.057 | 0.007 [0-0.027] |
Teaching (N = 22) | 0.069 | 0.091 | 0.122 | 0.236 | 0.558 | 0.558 | 0.046 [0.020-0.083]¥ |
Total (N = 67) | 0.057 | 0.069 | 0.119 | 0.236 | 0.558 | 0.558 | 0.028 [0.013-0.049] |
[I.C. 95 %] : 95% confidence interval.
¥ Significant statistical difference (p < 0.05) between non-teaching and teaching healthcare facilities.
Description of cases
In total, 67 colonizations (including 14 infections) of CPGNB were reported: 54 (80.6%) were identified in patients who acquired their CPGNB during a current hospital stay (9 infections and 51 colonizations), during a previous hospital stay (1 colonization) or in ambulatory care of the reporting facility (1 infection and 2 colonizations) (cat. 1a, 1b and 1c.). A total of 13 colonizations were associated to another facility (2 infections and 6 colonizations), to the community (2 colonizations) or remained unknown (2 infections and 5 colonizations) (cat. 2, 3 and 4) (table 3).
Table 3 – Cases of CPGNB Infections and Colonizations by Presumed Source of Acquisition, Québec, 2014–2015 (N, %)
Category | Source of Acquisition | Infection | Colonization* |
---|---|---|---|
1a | Healthcare-associated with a current hospital stay in the reporting facility | 9 (64.3 %) | 51 (76.1 %) |
1b | Healthcare-associated with a previous hospital stay in the reporting facility | 0 (0 %) | 1 (1.5 %) |
1c | Healthcare-associated with ambulatory care in the reporting facility | 1 (7.1 %) | 2 (3 %) |
1d | Healthcare-associated with long-term unit in the reporting facility | 0 (0 %) | 0 (0 %) |
1e | Healthcare-associated with psychiatry unit in the reporting facility | 0 (0 %) | 0 (0 %) |
2 | Healthcare-associated with another facility | 2 (14.3 %) | 6 (9 %) |
3 | Community | 0 (0 %) | 2 (3 %) |
4 | Unknown | 2 (14.3 %) | 5 (7.5 %) |
Total | 14 | 67 |
* Colonizations included infections.
In 2014-2015, among 14 infections, no primary bloodstream infection (BSI) was observed. However, two secondary bloodstream infections have been reported (Table 4).
Table 4 – Number of Cases of CPGNB Infections from All Sources by Type of Infection and Number of Complications (Secondary BSIs), Québec, 2014–2015 (N = 14)
Type of Infection | Infections (N) | Secondary Bloodstream Infections (N) |
---|---|---|
Primary BSI | ||
CRBSI-MBI | 0 | - |
CRBSI | 0 | - |
Non- CRBSI-MBI | 0 | - |
Non-CRBSI | 0 | - |
HD | 0 | - |
Others | ||
Surgical site | 5 | 0 |
Urinary tract | 3 | 0 |
Abdominal | 3 | 1 |
Pulmonary | 2 | 1 |
Skin and soft tissus | 1 | 0 |
Bones and joints | 0 | 0 |
Others | 0 | 0 |
Total | 14 | 2 |
BSI : bloodstream infection
CRBSI : catheter-related bloodstream infection
MBI : mucosal barrier injury
Non-CRBSI : non-catheter-related primary bloodstream infection
HD: hemodialysis
A total of 5 deaths within 30 days were observed, yielding an all cause case-fatality of 35.7% (Table 5).
Table 5 – Number of Deaths and 30-days all cause case-fatality in Patients Infected by a CPGNB, Québec, 2014-2015
2014-2015 | |
---|---|
CPGNB infections (all sources) | 14 |
Number of deaths | 5 |
All cause case-fatality | 35.7 % |
Table 6 – Risk Factors Associated With CPGNB colonization, Québec, 2014-2015
Risk Factors | New carrier | Known carrier N = 3 | Undefined carrier N = 13 | |
---|---|---|---|---|
No contact with a known carrier N = 42 | Contact with a known carrier N = 9 | |||
Contact with known carrier | - | 9 | - | 7 |
Healthcare abroad | 3 | - | - | 2 |
Travel abroad in the last 12 months | 8 | - | - | - |
Other risks | ||||
Carba-3GC*-Fluo | 3 | 1 | - | 4 |
No Carba-3GC-Fluo | 7 | 1 | - | - |
Diabetes | 4 | - | - | 2 |
Acute renal failure | 2 | - | 1 | - |
Chronic renal failure | - | - | 1 | 2 |
Non hematologic active neoplasia | 13 | 2 | 1 | - |
Solid organ transplant | 3 | - | - | - |
* 3GC: 3rd generation cephalosporin.
Carba-3GC-Fluo: Taking a carbapenem / 3rd generation cephalosporin / fluoroquinolone in the last two weeks prior to diagnosis.
Carba-3GC-Fluo: Taking a carbapenem / 3rd generation cephalosporin / fluoroquinolone in the last two weeks prior to diagnosis.
Colonization Screening Protocol
In 2014-2015, the acquisition rate of healthcare-associated CPGNB colonization (cat. 1a + 1b) was 0.16 / 10,000 patient days (table 7).
Table 7 – Change in the Number of Cases and Acquisition Rate of Healthcare-associated CPGNB Colonization (Cat. 1a + 1b) by Type of Healthcare Facility, Québec, 2014-2015 (Acquisition Rate of Healthcare-Associated CPGNB Colonization per 10,000 patient-days)
2014-2015 | ||
---|---|---|
Type of Facility | Number of Colonization | Acquisition Rate of HA-CPGNB Colonization |
Non-teaching (N = 45) | 33 | 0.22 [0.15-0.31] |
Teaching (N = 22) | 19 | 0.11 [0.07-0.16] |
Total (N = 67) | 52 | 0.16 [0.12-0.21] |
Table 8 shows the number of non-teaching facilities that identified the type of screening used at admission (29 out of 45) and during hospitalization (26 out of 45). About two-thirds of teaching facilities identified the type of screening used at admission (16 out of 22) and during hospitalization (16 out of 22).
Table 8 – Number of Healthcare Facilities that Identified the type of Screening Procedure Used at Admission and During Hospitalization by Type of Facility, Québec, 2014-2015
Number of Facilities That Identified the Type of Screening Procedure Used* | |||
---|---|---|---|
Type of Facility | At admission | During Hospitalization | Total |
Non-teaching (N = 45) | 29 | 26 | 33 |
Teaching (N = 22) | 16 | 16 | 17 |
Total (N = 67) | 45 | 42 | 50 |
* The "at admission" and "during hospitalization" categories are not mutually exclusives.
Tables 9 and 10 feature the total number of screening tests performed at admission and during hospitalization, as well as the mean number of CPGNB screening tests per admission.
Table 9 – Total Number of Screening Tests Performed at Admission and During Hospitalization by Type of Healthcare Facility, Québec, 2014-2015
Total Number of Screening Tests | ||||
---|---|---|---|---|
Type of Facility | At admission | During Hospitalization | Unspecified | Total |
Non-teaching | 2,619 | 8,102 | 795 | 11,516 |
Teaching | 10,686 | 17,417 | 29 | 28,132 |
Total | 13,305 | 25,519 | 824 | 39,648 |
Table 10 – Mean Number of CPGNB Screening Tests by Type of Healthcare Facility, Québec, 2014-2015 (Mean CPGNB Screening Tests per Admission)
Mean Number of CPGNB Screening Tests | |||
---|---|---|---|
Type of Facility | At admission | During Hospitalization | Total (N) |
Non-teaching | 0.013 | 0.040 | 0.057 |
Teaching | 0.046 | 0.075 | 0.121 |
Total | 0.031 | 0.059 | 0.092 |
Microbiology
Figure 1 features the distribution of microorganisms isolated from all cases. A total of 35 colonizations were due to Citrobacter freundii (52 %), 11 colonizations were due to Klebsiella pneumonia (16 %) and 7 were due to Enterobacter cloacae (10 %). Most deaths occurred in patients with KPC-producing Klebsiella pneumonia (n = 5; 62.5%). All 8 deaths occurred in patients with KPC-producing microorganisms.
Figure 1 – Categories of Isolated Microorganisms for all Cases (n = 67) and for Deaths at 30 days (N = 8), Québec, 2014-2015
Isolated Microorganisms - All Cases
Isolated Microorganisms – Deaths at 30 Days (N = 8)
Table 11 presents the resistance profile as reported by the healthcare facilities towards carbapenems of all reported microorganisms (colonization and infection). All the E. coli, K. oxytoca, S. marcescens and Serratia spp. were ertapenem resistant (100%). All the A. baumanii, E. cloacae, E. coli, K. oxytoca, Klebsiella spp, and Serratia spp. were meropenem resistant (100%).
Table 11 – Resistance Profile Towards Carbapenem of CPGNB Microorganisms isolated, Québec, 2014-2015
Microorganism | N | Antibiotics | Resistants | |
---|---|---|---|---|
N | % | |||
Acinetobacter baumannii | 3 | Doripenem | 2 | 66.7 |
Imipenem | 3 | 100.0 | ||
Meropenem | 3 | 100.0 | ||
Citrobacter freundii | 35 | Ertapenem | 32 | 91.4 |
Imipenem | 12 | 34.3 | ||
Meropenem | 28 | 80.0 | ||
Enterobacter cloacae | 7 | Ertapenem | 4 | 57.1 |
Imipenem | 6 | 85.7 | ||
Meropenem | 7 | 100.0 | ||
Escherichia coli | 5 | Ertapenem | 5 | 100.0 |
Imipenem | 4 | 80.0 | ||
Meropenem | 5 | 100.0 | ||
Klebsiella oxytoca | 4 | Ertapenem | 4 | 100.0 |
Imipenem | 2 | 50.0 | ||
Meropenem | 4 | 100.0 | ||
Klebsiella pneumoniae | 12 | Ertapenem | 11 | 91.7 |
Imipenem | 9 | 75.0 | ||
Meropenem | 11 | 91.7 | ||
Klebsiella spp. | 1 | Ertapenem | 1 | 100.0 |
Meropenem | 1 | 100.0 | ||
Serratia marcescens | 1 | Ertapenem | 1 | 100.0 |
Imipenem | 1 | 100.0 | ||
Serratia spp. | 1 | Ertapenem | 1 | 100.0 |
Imipenem | 1 | 100.0 | ||
Meropenem | 1 | 100.0 |
Table 12 shows the carbapenemase gene detected for every microorganisms reported during the surveillance period (colonization and infection). Among the 67 cases, one infection was associated with two different CPGNB (1 NDM-producing Escherichia coli and 1 OXA-48 producing Klebsiella pneumonia). Also, one patient was colonizationed by two different CPGNB (1 KPC-producing Escherichia coli and 1 KPC-producing Klebsiella oxytoca). Finally, one Klebsiella pneumonia strain produced both OXA-48 and NDM.
Table 12 – Distribution of Carbapenemase-encoding Genes from Reported Microorganisms, Québec, 2014-2015
Microorganism | No Isolated | Gene | N | % gene among microorganism |
---|---|---|---|---|
Acinetobacter baumannii | 3 | OXA-23 | 3 | 100.0 |
Citrobacter freundii | 35 | KPC | 35 | 100.0 |
Enterobacter cloacae | 7 | KPC | 6 | 85.7 |
NMC | 1 | 14.3 | ||
Escherichia coli | 5 | KPC | 1 | 20.0 |
NDM | 3 | 60.0 | ||
OXA-48 | 1 | 20.0 | ||
Klebsiella oxytoca | 4 | KPC | 4 | 100.0 |
Klebsiella pneumoniae | 12 | KPC | 9 | 69.2 |
OXA-48 | 1 | 7.7 | ||
OXA-48/NDM | 1 | 7.7 | ||
VIM | 1 | 7.7 | ||
Other Klebsiella spp. | 1 | OXA-48 | 1 | 100.0 |
Serratia marcescens | 1 | SME | 1 | 100.0 |
Serratia spp. | 1 | SME | 1 | 100.0 |
Total | 69 |
KPC: Klebsiella pneumonia carbapenemase (Class A).
NDM: New-Dehli metallo--lactamase (Class B).
NMC: Not metalloenzyme carbapenemase.
OXA-23: Oxacillinase-23 (Class D).
OXA-48: Oxacillinase-48 (Class D).
SME: Serratia marcescens enzyme.
VIM: Verona integron-encoded metallo--lactamase (Class B).
Data per Facility
The incidence rate of HA-CPGNB infection and the percentile rankings by type of facility are shown in figure 2 and 3. Figure 4 and 5 present the rate of acquisition of healthcare-associated colonization by type of facility.
Figure 2 – Incidence Rate and Percentile Ranking of Healthcare-Associated CPGNB infection (Cat. 1a + 1b) for Non-Teaching Healthcare Facilities, Québec, 2014-2015 (Incidence Rate per 10,000 Patient-Days)
NB: Facilities 9, 11, 16, 23, 26, 32, 34, 35, 36, 37, 40, 42, 45, 46, 47, 49, 52, 53, 56, 58, 61, 63, 64, 65, 67, 71, 74, 75, 77, 81, 82, 83, 84, 85, 88, 89, 91, 97, 100, 103, 107, 109, 113 and 130 did not report any cases of infection in 2014-2015.
Figure 3 – Incidence Rate and Percentile Ranking of Healthcare-Associated CPGNB Infection (Cat. 1a + 1b) for Teaching Healthcare Facilities, Québec, 2014-2015 (Incidence Rate per 10,000 Patient-Days)
NB: Facilities 2, 6, 8, 12, 13, 15, 18, 20, 21, 24, 27, 28, 30, 31, 116 and 118 did not report any cases of infection in 2014-2015.
Figure 4 – Acquisition Rate of Healthcare-Associated CPGNB Colonization (Cat.1a + 1b) for Non-Teaching Healthcare Facilities, Québec, 2014-2015 (Acquisition Rate of Healthcare-Associated CPGNB Colonization per 10,000 Patient-Days)
NB: Facilities 9, 11, 16, 23, 26, 32, 34, 35, 36, 37, 40, 42, 45, 46, 47, 49, 52, 53, 56, 61, 63, 64, 65, 67, 71, 74, 75, 77, 81, 82, 83, 84, 85, 88, 89, 91, 97, 100, 103, 107, 109, 113 and 130 did not report any cases of colonization in 2014-2015.
Figure 5 – Acquisition Rate of Healthcare-Associated CPGNB Colonization (Cat.1a + 1b) for Teaching Healthcare Facilities, Québec, 2014-2015 (Acquisition Rate of Healthcare-Associated CPGNB Colonization per 10,000 Patient-Days)
NB: Facilities 2, 6, 8, 12, 13, 15, 18, 20, 21, 24, 27, 28, 30, 31, 116 et 118 did not report any cases of colonization in 2014-2015.
At the local level, in 2014-2015, the incidence rate of HA-CPGNB infections ranged from 0 to 0.56 / 10,000 patient-days, whereas the acquisition rate of HA-CPGNB colonization ranged from 0 to 4.81 / 10,000 patient-days. A total of 60 facilities (89.6%) did not report any HA-CPGNB infection or colonization in 2014-2015. A detailed summary of the surveillance data for HA-CPGNB infection by healthcare facility can be found in table 13.
Table 13 – Incidence Rate of Healthcare-Associated CPGNB Infection (cat. 1a + 1b), Acquisition Rate of Healthcare-Associated CPGNB Colonization and Mean CPGNB Screening Tests by Admission and by Facility, Québec, 2014-2015 (Incidence Rate per 10,000 Patient-Days [95% CI]; Acquisition Rate of Colonization per 10,000 Patient-Days)
Health Region | Facility | Incidence Rate of HA-CPGNB Infection (cat. 1a + 1b) [95% CI] | Acquisition Rate of HA-CPGNB Colonization (cat. 1a + 1b) | Mean CPGNB Screening Tests per Admission* | |
---|---|---|---|---|---|
Number | Name | ||||
01 | 16 | HÔPITAL RÉGIONAL DE RIMOUSKI | 0 | 0 | 0.149 |
32 | CENTRE HOSPITALIER RÉGIONAL DU GRAND-PORTAGE | 0 | 0 | 0.016 | |
61 | HÔPITAL NOTRE-DAME-DE-FATIMA | 0 | 0 | 0.011 | |
71 | HÔPITAL DE MATANE | 0 | 0 | 0.002 | |
77 | HÔPITAL D'AMQUI | 0 | 0 | - | |
84 | HÔPITAL DE NOTRE-DAME-DU-LAC | 0 | 0 | - | |
BAS-SAINT-LAURENT | 0 | 0 | 0.070 | ||
02 | 20 | HÔPITAL DE CHICOUTIMI | 0 | 0 | 0 |
67 | HÔPITAL ET CENTRE DE RÉADAPTATION DE JONQUIÈRE | 0 | 0 | 0.137 | |
74 | HÔPITAL DE DOLBEAU-MISTASSINI | 0 | 0 | 0.002 | |
88 | HÔPITAL, CLSC ET CENTRE D'HÉBERGEMENT DE ROBERVAL | 0 | 0 | - | |
100 | HÔPITAL DE LA BAIE | 0 | 0 | - | |
SAGUENAY–LAC-SAINT-JEAN | 0 | 0 | 0.021 | ||
03 | 2 | HÔPITAL DE L'ENFANT-JÉSUS | 0 | 0 | 0.066 |
7 | PAVILLON L'HÔTEL-DIEU DE QUÉBEC | 0.12 [0-0.47] | 0.12 | 0.015 | |
24 | HÔPITAL DU SAINT-SACREMENT | 0 | 0 | 0.021 | |
27 | PAVILLON CENTRE HOSPITALIER DE L'UNIVERSITÉ LAVAL | 0 | 0 | 0.014 | |
28 | PAVILLON SAINT-FRANÇOIS D'ASSISE | 0 | 0 | 0.006 | |
33 | INSTITUT UNIVERSITAIRE DE CARDIOLOGIE ET DE PNEUMOLOGIE DE QUÉBEC | 0.13 [0-0.49] | 0.50 | 0.184 | |
CAPITALE-NATIONALE | 0.04 [0-0.10] | 0.09 | 0.051 | ||
04 | 23 | HÔTEL-DIEU D'ARTHABASKA | 0 | 0 | 0.007 |
31 | PAVILLON SAINT-JOSEPH | 0 | 0 | 0.004 | |
85 | CENTRE DE SANTÉ ET DE SERVICES SOCIAUX DU HAUT-SAINT-MAURICE | 0 | 0 | - | |
MAURICIE ET CENTRE-DU-QUÉBEC | 0 | 0 | 0.005 | ||
05 | 15 | HÔPITAL FLEURIMONT | 0 | 0 | - |
30 | HOTEL-DIEU DE SHERBROOKE | 0 | 0 | - | |
49 | CENTRE DE SANTÉ ET DE SERVICES SOCIAUX MEMPHRÉMAGOG | 0 | 0 | - | |
75 | CENTRE DE SANTÉ ET DE SERVICES SOCIAUX DU GRANIT | 0 | 0 | - | |
ESTRIE | 0 | 0 | 0 | ||
06 | 3 | HÔPITAL ROYAL VICTORIA | 0.09 [0-0.36] | 0.09 | 0.015 |
4 | HÔPITAL NOTRE-DAME DU CHUM | 0.56 [0.05-1.60] | 0.84 | - | |
5 | HÔPITAL GÉNÉRAL JUIF | 0.07 [0-0.27] | 0.56 | 1.280 | |
6 | L'HÔPITAL DE MONTRÉAL POUR ENFANTS | 0 | 0 | 0.002 | |
8 | PAVILLON MAISONNEUVE/PAVILLON MARCEL-LAMOUREUX | 0 | 0 | 0.066 | |
12 | CENTRE HOSPITALIER UNIVERSITAIRE SAINTE-JUSTINE | 0 | 0 | - | |
13 | INSTITUT DE CARDIOLOGIE DE MONTRÉAL | 0 | 0 | 0.090 | |
21 | HÔPITAL SAINT-LUC DU CHUM | 0 | 0 | - | |
26 | HÔPITAL DE VERDUN | 0 | 0 | 0.011 | |
29 | HÔPITAL GÉNÉRAL DE MONTRÉAL | 0.24 [0.02-0.68] | 0.24 | 0.061 | |
34 | HÔPITAL SANTA CABRINI | 0 | 0 | - | |
36 | HÔPITAL GÉNÉRAL DU LAKESHORE | 0 | 0 | 0.964 | |
83 | HÔPITAL DE LASALLE | 0 | 0 | 0.014 | |
116 | INSTITUT THORACIQUE DE MONTRÉAL | 0 | 0 | 0.024 | |
118 | HÔPITAL NEUROLOGIQUE DE MONTRÉAL | 0 | 0 | 0.034 | |
MONTRÉAL | 0.07 [0.03-0.14] | 0.16 | 0.257 | ||
07 | 40 | HÔPITAL DE HULL | 0 | 0 | 0.001 |
OUTAOUAIS | 0 | 0 | 0.001 | ||
08 | 47 | HÔPITAL DE ROUYN-NORANDA | 0 | 0 | 0.028 |
52 | HÔPITAL D'AMOS | 0 | 0 | 0.001 | |
65 | HÔPITAL ET CLSC DE VAL-D'OR | 0 | 0 | - | |
82 | PAVILLON SAINTE-FAMILLE | 0 | 0 | 0.102 | |
ABITIBI-TÉMISCAMINGUE | 0 | 0 | 0.019 | ||
09 | 64 | HÔPITAL LE ROYER | 0 | 0 | 0.009 |
CÔTE-NORD | 0 | 0 | 0.009 | ||
11 | 53 | HÔPITAL DE CHANDLER | 0 | 0 | - |
91 | HÔPITAL HÔTEL-DIEU DE GASPÉ | 0 | 0 | - | |
97 | HÔPITAL DE MARIA | 0 | 0 | 0.024 | |
107 | HÔPITAL DE L'ARCHIPEL | 0 | 0 | 0.031 | |
109 | HÔPITAL DE SAINTE-ANNE-DES-MONTS | 0 | 0 | 0.013 | |
GASPÉSIE–ÎLES-DE-LA-MADELEINE | 0 | 0 | 0.012 | ||
12 | 18 | HÔTEL-DIEU DE LÉVIS | 0 | 0 | 0.009 |
63 | HÔPITAL DE SAINT-GEORGES | 0 | 0 | 0.003 | |
89 | HÔPITAL DE MONTMAGNY | 0 | 0 | 0.088 | |
113 | HÔPITAL DE THETFORD MINES | 0 | 0 | 0.013 | |
CHAUDIÈRE-APPALACHES | 0 | 0 | 0.017 | ||
13 | 19 | HÔPITAL CITÉ DE LA SANTÉ | 0.06 [0-0.22] | 0.34 | 0.115 |
LAVAL | 0.06 [0-0.22] | 0.34 | 0.115 | ||
14 | 11 | HÔPITAL PIERRE-LE GARDEUR | 0 | 0 | 0.020 |
LANAUDIÈRE | 0 | 0 | 0.020 | ||
15 | 45 | HÔPITAL DE SAINT-EUSTACHE | 0 | 0 | 0.007 |
56 | CENTRE DE SANTÉ ET DE SERVICES SOCIAUX D'ARGENTEUIL | 0 | 0 | 0.043 | |
81 | HÔPITAL DE MONT-LAURIER | 0 | 0 | 0.004 | |
103 | HÔPITAL LAURENTIEN | 0 | 0 | 0.002 | |
LAURENTIDES | 0 | 0 | 0.008 | ||
16 | 9 | HÔPITAL DU HAUT-RICHELIEU | 0 | 0 | 0 |
35 | HÔPITAL HONORÉ-MERCIER | 0 | 0 | 0.027 | |
37 | HÔTEL-DIEU DE SOREL | 0 | 0 | 0.001 | |
42 | CENTRE HOSPITALIER ANNA-LABERGE | 0 | 0 | 0.060 | |
46 | HÔPITAL DE GRANBY | 0 | 0 | - | |
58 | HÔPITAL DU SUROÎT | 0 | 4.81 | 0.373 | |
130 | HÔPITAL BARRIE MEMORIAL | 0 | 0 | 0.487 | |
MONTÉRÉGIE | 0 | 0.70 | 0.75 | ||
Total | 0.03 [0.01-0.05] | 0.16 | 0.092 |
* Number of screening test divided by number of admisions.
Author
Comité de surveillance provinciale des infections nosocomiales (SPIN)
Editorial Committee
Christophe Garenc, Direction des risques biologiques et de la santé au travail, Institut national de santé publique du Québec
Muleka Ngenda-Muadi, Direction des risques biologiques et de la santé au travail, Institut national de santé publique du Québec
Mélissa Trudeau, Direction des risques biologiques et de la santé au travail, Institut national de santé publique du Québec
Christian Lavallée, Hôpital Maisonneuve-Rosemont